Fig. 1. The composite analysis of the risk of major adverse cardiovascular events (MACEs) from three cardiovascular outcome trials, expressed as relative.

Slides:

Advertisements

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Advertisements

Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aspirin for the Prevention of Cardiovascular Events.

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduced-Function CYP2C19 Genotype and Risk of Adverse.

Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.

Clinical Outcomes with Newer Antihyperglycemic Agents

Clinical Outcomes with Newer Antihyperglycemic Agents

Mikhail Kosiborod, MD Professor of Medicine (Cardiology)

The SPRINT Research Group

From: Risks of Cardiovascular Adverse Events and Death in Patients with Previous Stroke Undergoing Emergency Noncardiac, Nonintracranial Surgery:The Importance.

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis Stavros Stavrakis, MD The American Journal.

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

Cardiovascular Outcomes Trials with Antihyperglycemic Agents

Copyright © 2005 American Medical Association. All rights reserved.

LEADER trial: Primary Outcome

Benefits and risks of using clopidogrel before coronary artery bypass surgery: Systematic review and meta-analysis of randomized trials and observational.

Pravastatin in Elderly Individuals at Risk of Vascular Disease

Cardiovascular Outcomes Trials with Antihyperglycemic Agents

New Insights from EXSCEL

Cycloset®A Dopamine Receptor Agonist Cycloset® -Bromocriptine: Safety Trial: Post Hoc Analysis of Cumulative Percent MACE Endpoint Bromocriptine (Parlodel)

CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study

First time a CETP inhibitor shows reduction of serious CV events

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

Updates on CVOT Data and Clinical Comparisons That Matter

on behalf of the LEADER Trial Steering Committee and Investigators

Updates on Outcomes for Novel T2D Therapies

Novel Developments & Latest Clinical Results With Long-Acting GLP-1 Receptor Agonists.

Impacting CV Risk With Diabetes Medications

Impacting CV Risk With Diabetes Medications

Introduction The American Journal of Medicine

Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist.

Tackling CV Risk in T2DM.

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

LEADER One Year On.

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

Antihyperglycemic Therapy

CV Outcomes and Adherence With GLP-1 RAs

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Disease—A Meta-Analysis.

Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease Johannes F.E. Mann, Qi-Long.

Potential mechanisms whereby statins may reduce the risk of stroke

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

Svend A. Mortensen et al. JCHF 2014;2:

Berger JS, et al. JAMA 2009;301:

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Pulse pressure for selecting the optimal cardiac strategy in patients with type 2 diabetes and coronary artery disease Tetsuro Tsujimoto, Hiroshi Kajio

Role of Niacin in Current Clinical Practice: A Systematic Review

CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management G. B. John Mancini, MD, Alice.

Results of sensitivity analyses.

Volume 80, Issue 6, Pages (September 2011)

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

CANVAS programe subanalyses HR (95%CI): 0.65 ( ) ( ) ( ) ( )

New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

Christian Madelaire et al. JCHF 2018;6:

M. Hassan Murad, MD, MPH, David N. Flynn, BS, Mohamed B

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?

Presentation transcript:

Fig. 1. The composite analysis of the risk of major adverse cardiovascular events (MACEs) from three cardiovascular outcome trials, expressed as relative risk (RR): (A) three-point MACE, (B) cardiovascular death, (C) non-fatal myocardial infarction, and (D) non-fatal stroke. CI, confidence interval; GLP-1, glucagon-like peptide 1; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; SUSTAIN-6, Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes; EXSCEL, Exenatide Study of Cardiovascular Event Lowering Trial. Fig. 1. The composite analysis of the risk of major adverse cardiovascular events (MACEs) from three cardiovascular outcome trials, expressed as relative risk (RR): (A) three-point MACE, (B) cardiovascular death, (C) non-fatal myocardial infarction, and (D) non-fatal stroke. CI, … Diabetes Metab J. 2019 Aug;43(4):410-421. https://doi.org/10.4093/dmj.2018.0070